ABUSArbutus Biopharma Corporation
$4.18-2.7% 1Y
$4.18
$3.6752 weeks$5.20
The financials
Arbutus Biopharma Corporation by the numbers
Arbutus Biopharma Corporation (ABUS) reported revenue of $1.0M in Q2 2026 (quarter ended Jun 30, 2026), down 91% from the same quarter a year earlier. That came with net loss of $5.1M. For the full year FY2025, revenue was $14M (+128% year on year) and net income −$34M. Its largest product in Q2 2026 was License at $632K, 62% of the disclosed total, well ahead of Collaboration And Contracts at 20%. The next results filing is expected around Nov 12, 2026, the same week as a year ago.
| Income statement | Q2 2026 | Q2 2025 | Change |
|---|---|---|---|
| Revenue | $1.0M | $11M | −91% |
| Operating income | −$6.0M | $1.5M | to a loss |
| Net income | −$5.1M | $2.5M | to a loss |
| Diluted EPS | −$0.03 | $0.01 | to a loss |
| Product | Revenue | Share |
|---|---|---|
| License | $632K | 62% |
| Collaboration And Contracts | $202K | 20% |
| Non-Cash Royalty | $180K | 18% |
Business segments
Revenue split by product segment, from SEC XBRL filings.
Latest period: Jun 2026Total $1.0M (-99%)
Non-Cash Royalty grew -66% year on yearCollaboration And Contracts -98% year on year
Segment Latestquarter on quarteryear on year
- License$632.0K$632.0Kquarter on quarter -100%year on year n/a-100%n/a
- Collaboration And Contracts$202.0K$202.0Kquarter on quarter -0.98%year on year -98%-0.98%-98%
- Non-Cash Royalty$180.0K$180.0Kquarter on quarter -0.55%year on year -66%-0.55%-66%